BASEL, Switzerland – January 16, 2026 – Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease, today announced that results from its Phase 1b/2 clinical trial of NOUS-209 in Lynch Syndrome (LS) carriers have been published in Nature Medicine (D’Alise et al). Publication of the results in a leading high-impact medical journal marks a key milestone for Nouscom and advances the emerging field of cancer interception, reinforcing the potential of NOUS-209 to transform preventive care for LS carriers.
